CYP2C19 STATUS AND OUTCOMES IN THE EUCLID TRIAL

Manesh R. Patel,Gretchen Heizer,Kenneth Mahaffey,F. Gerry Fowkes,Jeffrey Berger,Iris Baumgartner,Frank Rockhold,Peter Held,Brian Katona,Lars Norgren,William Jones,Juuso Blomster,William Hiatt

Journal of the American College of Cardiology（2018）

引用 0|浏览51

暂无评分

摘要

Cytochrome P450 2C19 (CYP2C19) is a hepatic enzyme involved in metabolism of clopidogrel to its active metabolite. Polymorphisms with 2 loss-of-function (LOF) alleles lead to poor metabolism of clopidogrel, but little is known about the effects of both heterozygous state for LOF and gain-of-function

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要